

Lenacapavir Resistance Analysis in a Phase 1b Clinical Proof-Of-Concept Study

Nicolas Margot, Renee Ram, PC Parvangada, Ross Martin, Rob Hyland, Martin Rhee, Christian Callebaut

GILEAD
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404
650-574-3000


Poster O-324

Gilead Sciences, Inc., Foster City, California, USA

Introduction


- Lenacapavir (LEN, GS-6207): first-in-class inhibitor of HIV-1 capsid function (Link 2020)
- High potency in vitro (30 – 100 pM); selectivity >140,000
- No cross-resistance against NRTI, NNRTI, PI, INSTI, MI
- In vitro resistance selections with LEN: 7 mutations identified in HIV-1 capsid protein (CA), at L56I, M66I, Q67H, K70N, N74D, N74S and T107N; associated with reduced susceptibility to LEN, with reduced fitness (Link 2020)
- RAMs: not found in naïve/experienced PLWH (Marcelin 2020)
- Active in vitro on primary viruses from TN, TE (Margot 2019)
- Administered subcutaneously (SC) Q6M as a long acting inhibitor (Begley 2020)
- Phase 1b proof-of-concept dose-finding study in people living with HIV (PLWH): single SC injection of LEN 20, 50, 150, 450, or 750 mg (Link 2020, Daar 2020)
- Potent antiviral activity: up to 2.3 log₁₀ decline in HIV-1 RNA after 9 days of monotherapy (Link 2020, Daar 2020)
- Here we describe the resistance analyses for all participants

LEN: first-in-class HIV capsid inhibitor



- LEN binds between 2 adjacent CA monomers; binding alters assembly / disassembly of CA core (multi-stage effect)

LEN binding to HIV-1 capsid protein



CTD, C-terminal domain; NTD, N-terminal domain.
Yant et al, CROI 2019.

- Pocket naturally binds nuclear import factors necessary for virus replication

Phenotype of HIV-1 encoding *in vitro* emergent variants

HIV-1 CA Sequence	WT	Q67H	N74D	K70N	Q67H N74S	Q67H T107N	L56I	Q67H N74D	M66I
Fold resistance to LEN*	1	6	22	24	32	62	239	1,099	>3,200
Replication level (% WT) in primary CD4+ T-cells†	100	100	1	ND	ND	28	3	<1	<1

*Data are mean mutant/wild-type (WT) EC₅₀ ratios from triplicate cell cultures, n = 3. †Data are % of the WT virus from six replicate cell cultures, n = 2. Cells infected with a replication competent reporter HIV-1. EC₅₀, half maximal effective concentration. ND, not determined.
Link et al, Nature 2020

Prevalence of LEN *in vitro* RAMs in Clinical Isolates (N=1500)


LEN RAMs (<i>in vitro</i> -selected)	ARV-naïve (n=500)	ARV-experienced (no PI use) (n=500)	ARV-experienced (PI failure history) (n=500)
L56I	0%	0%	0%
M66I	0%	0%	0%
Q67H	0%	0%	0%
K70N	0%	0%	0%
N74D	0%	0%	0%
N74S	0%	0%	0%
T107N	0%	0%	0%

Subtype B, AG, F1, CRF 06_A1, D and other non-B represented. RAM: resistance-associated mutation
Marcelin et al, JAC 2020.

- Lack of pre-existing resistance to LEN
- Failure on PI treatment does not lead to resistance to LEN

Phase 1b LEN monotherapy: Study design


Dose-Ranging Study: GS-US-200-4072



*2 from each dose cohort. 8 participants from each dose cohort (7 for the 750 mg cohort) were randomised to receive either active treatment (n=6 and n=5 for the 750 mg cohort) or placebo (n=2).

- Phase 1b, double-blind, randomised, placebo-controlled, dose-ranging study (NCT03739866)
- 39 participants enrolled: 29 receiving LEN and 10 receiving placebo
- Primary endpoint: maximum reduction of plasma HIV-1 RNA through Day 10
- All participants required to start B/F/TAF on Day 10

Subcutaneous LEN: antiviral activity



Daar et al, EACS 2019; Daar et al, CROI 2020.

Methods

- Study 4072 is a double-blind, placebo-controlled, dose-ranging, randomized (3:1; n=8/group) study in PLWH who were capsid inhibitor-naïve
- Resistance analyses were performed for all participants prior to study entry and at the end of monotherapy using genotypic and phenotypic Gag-Pro assays
 - Monogram Biosciences: next-generation sequencing (NGS) assay reporting mutations present in >10% of reads. Gag-PR sequence from participants was cloned into gag-PR-deleted NL 4-3-based test vector for phenotypic testing (single-cycle assay)
 - Seq-IT: NGS genotyping assay (2% limit of detection).
- Samples were evaluated for the emergence of CA mutations and/or change in phenotypic susceptibility to LEN.

Results

- In the pre-treatment analysis, no participants had HIV-1 harboring resistance mutations to LEN, with all having wild-type (WT) phenotypic susceptibility to LEN
- Post-monotherapy analyses revealed the emergence of CA mutation Q67H at Day 10 in 2 participants
- One participant (20 mg group) had a Q67Q/H mixture detected in two separate NGS analyses, and another participant (50 mg group) had a Q67H mutation, detected in one of the NGS analyses
- No other substitutions were observed in the CA protein



Plasma HIV-1 RNA levels and genotype in PLWH (GS-US-200-4072)

LEN Dose	Participant ID	BL HIV-1 RNA (log ₁₀ copies/mL)	Max. HIV-1 RNA change (day 9) (log ₁₀ copies/mL)	CA genotype (day 9) (Monogram; NGS>10%)*	CA genotype (day 9) (Seq-IT; NGS>2%)*
20 mg	20-1	4.84	-0.83	wild-type	wild-type
	20-2	3.86	-1.58	wild-type	wild-type
	20-3	4.90	-1.74	Q67Q/H†	Q67Q/H
	20-4	4.19	-1.43	wild-type	wild-type
	20-5	4.21	-1.33	wild-type	wild-type
	20-6	4.73	-1.21	ND	wild-type
50 mg	50-1	4.01	-2.39	ND	Q67H
	50-2	4.81	-1.55	wild-type	wild-type
	50-3	4.30	-1.61	wild-type	wild-type
	50-4	4.33	-2.32	ND	wild-type
	50-5	4.85	-1.16	wild-type	wild-type
	50-6	4.32	-1.73	ND	wild-type
150 mg	150-1	4.61	-2.06	ND	wild-type
	150-2	4.55	-1.68	wild-type	wild-type
	150-3	4.58	-1.86	wild-type	wild-type
	150-4	4.25	-1.49	ND	wild-type
	150-5	4.61	-1.87	wild-type	wild-type
	150-6	4.31	-1.62	ND	wild-type
450 mg	450-1	4.31	-2.32	ND	wild-type
	450-2	4.38	-2.86	ND	wild-type
	450-3	4.53	-2.11	ND	wild-type
	450-4	4.84	-1.83	wild-type	wild-type
	450-5	4.44	-1.58	wild-type	wild-type
	450-6	4.62	-2.52	ND	wild-type
750 mg	750-1	4.74	-2.87	wild-type	wild-type
	750-2	4.94	-1.48	wild-type	wild-type
	750-3	4.35	-3.02	ND	ND
	750-4	4.17	-1.95	wild-type	wild-type
	750-5	4.60	-1.98	wild-type	wild-type

ND, not determined.
Link et al, Nature; Daar et al CROI 2020; Margot et al HIV Glasgow 2020.
(*) Mutations from next-generation sequencing (NGS) assays found in >10% or >2% of reads were reported.
(†) Phenotypic fold-change from WT: 1.6


Results (Cont'd)

Participants with Emerging LEN Resistance



B/F/TAF: bictegravir/emtricitabine/tenofovir alafenamide; WT: Wild-type

Dose-Response Relationship



- Maximum reduction observed between 50 and 150 mg doses
- Near maximal antiviral activity observed at mean concentrations ≥4.4 ng/mL (IQ>1.1)
- 6-month Phase 2/3 dosing: LEN C_{min} = 24 ng/mL → IQ>6, low probability of resistance emergence

Conclusions

- In this Phase 1 study, single SC doses of LEN resulted in potent antiviral activity over 10 days
- Rare low-level resistance to LEN via a single mutation (Q67H) emerged only at LEN exposures below the expected exposure in Ph2/3 studies
- Previous *in vitro* characterization identified that Q67H mutation had the least impact on viral fitness and susceptibility to LEN, which may explain its emergence at lower LEN exposures
- These results support further evaluation of LEN as a long-acting antiretroviral agent in PLWH

References

Yant et al, CROI 2019; Sager et al, CROI 2019; Margot et al, EACS 2019; Marcelin et al, EACS 2019; Daar et al, EACS 2019; Daar et al, CROI 2020; Link et al, Nature, 2020; Margot et al, CROI 2020; Marcelin et al, JAC 2020; Begley et al, AIDS2020

Acknowledgments

Study Participants and their Families. Study Investigators and Staff: Dr. Paul Benson, Dr. Mezgebe Berhe, Dr. Gordon E. Crofoot, Dr. Eric Daar, Dr. Edwin DeJesus, Dr. Cheryl McDonald, Dr. Anthony Mills, Dr. Olayemi Osiyemi, Dr. Moti N. Ramgopal, Dr. Peter J. Ruane, Dr. Gary Ian Sinclair, Dr. Sarah Waldman